Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01852890Phase 1Completed

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Role: lead

NCT02905578Phase 2Completed

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

Role: lead

NCT01515046Phase 2Terminated

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Role: lead

NCT01049880Phase 1Completed

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

Role: lead

All 4 trials loaded